Related Experiment Videos
[Microscopic polyangiitis]
Abstract:
Microscopic polyangiitis is a very rare disease characterized by the lesions of arteriolae, venulae and capillaries--mainly of the kidneys and lungs, but also of other systems and organs. The elevated titer of anti-myeloperoxidase ANCA is very important immunological indicator. The main changes in our patient were related to the lung bleeding and rapidly progressive glomerulonephritis. The treatment has started according to the standard Fauci scheme adjusted to the level of disease severity and the age of patient (prednisone 60 mg/24 h, along with the gradual dosage decrease, cyclophosphamide 150 mg/24 h) and has lead to the clinical-laboratory remission. The patient had the leukocyte values irregularly controlled during the immunosuppressive therapy and agranulocytosis thus caused was not spotted in time, leading to the inadequate treatment of pneumonia that brought on the lethal outcome.
Insights
Microscopic polyangiitis, a rare vasculitis, involves small blood vessels and is indicated by anti-myeloperoxidase ANCA. Early detection of complications like agranulocytosis during treatment is crucial for patient survival.
Area of Science:
- Internal Medicine
- Immunology
- Nephrology
Background:
- Microscopic polyangiitis (MPA) is a rare systemic vasculitis affecting small blood vessels, primarily in the kidneys and lungs.
- Anti-myeloperoxidase anti-neutrophil cytoplasmic antibodies (MPO-ANCA) are key serological markers for MPA diagnosis.
- MPA commonly presents with pulmonary hemorrhage and rapidly progressive glomerulonephritis.
Observation:
- A patient with MPA presented with significant lung bleeding and rapidly progressive glomerulonephritis.
- Treatment initiated with prednisone and cyclophosphamide achieved clinical-laboratory remission.
Findings:
- Despite initial remission, the patient developed agranulocytosis during immunosuppressive therapy.
- Delayed recognition of agranulocytosis led to undertreatment of subsequent pneumonia.
Implications:
- This case highlights the critical need for vigilant monitoring of leukocyte counts during immunosuppressive treatment for MPA.
- Prompt management of treatment-induced complications, such as agranulocytosis, is essential to prevent fatal outcomes.
- Understanding MPA's potential complications is vital for optimizing patient care and improving prognosis.